Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Cijeli opis

Bibliografski detalji
Glavni autori: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Format: Članak
Jezik:English
Izdano: Elsevier 2023-08-01
Serija:Journal of Allergy and Clinical Immunology: Global
Teme:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Online pristup:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Internet

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Slični predmeti